{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:35:09Z","timestamp":1787020509405,"version":"build-2736575974"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T00:00:00Z","timestamp":1746230400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T00:00:00Z","timestamp":1746230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82204414"],"award-info":[{"award-number":["No. 82204414"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004735","name":"Hunan\u00a0Provincial\u00a0Natural\u00a0Science\u00a0Foundation\u00a0of\u00a0China","doi-asserted-by":"crossref","award":["No. 2022JJ30789"],"award-info":[{"award-number":["No. 2022JJ30789"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004735","name":"Hunan\u00a0Provincial\u00a0Natural\u00a0Science\u00a0Foundation\u00a0of\u00a0China","doi-asserted-by":"crossref","award":["No.\u00a02022JJ30026"],"award-info":[{"award-number":["No.\u00a02022JJ30026"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Precision\u00a0Diagnosis\u00a0and\u00a0Treatment\u00a0Center\u00a0for\u00a0Lymphoma\u00a0in\u00a0Hunan\u00a0Province,\u00a0Hunan\u00a0Development\u00a0and\u00a0Reform\u00a0Commission\u00a0High-tech","award":["[2021]No.1073"],"award-info":[{"award-number":["[2021]No.1073"]}]},{"name":"Clinical\u00a0Research\u00a0Center\u00a0for\u00a0Lymphoma\u00a0in\u00a0Hunan\u00a0Province,\u00a0Hunan\u00a0Provincial\u00a0Clinical\u00a0Medical\u00a0Research\u00a0Center\u00a0for\u00a0Lymphatic\u00a0Tumors","award":["No.\u00a02021SK4015"],"award-info":[{"award-number":["No.\u00a02021SK4015"]}]},{"name":"National\u00a0Key\u00a0Clinical\u00a0Specialty\u00a0Construction\u00a0Project","award":["No. 2023-223"],"award-info":[{"award-number":["No. 2023-223"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"DOI":"10.1186\/s12935-025-03789-9","type":"journal-article","created":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T11:32:13Z","timestamp":1746271933000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Genomic signatures in plasma circulating tumor DNA reveal treatment response and prognostic insights in mantel cell lymphoma"],"prefix":"10.1186","volume":"25","author":[{"given":"Zhou","family":"Ouyang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruolan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caiqin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuxiang","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,3]]},"reference":[{"issue":"20","key":"3789_CR1","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375\u201390.","journal-title":"Blood"},{"issue":"5","key":"3789_CR2","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/ajh.26523","volume":"97","author":"P Jain","year":"2022","unstructured":"Jain P, Wang ML. Mantle cell lymphoma in 2022\u2014a comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. Am J Hematol. 2022;97(5):638\u201356.","journal-title":"Am J Hematol"},{"issue":"Suppl 1","key":"3789_CR3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/hon.3149","volume":"41","author":"E Silkenstedt","year":"2023","unstructured":"Silkenstedt E, Dreyling M. Mantle cell lymphoma-update on molecular biology, prognostication and treatment approaches. Hematol Oncol. 2023;41(Suppl 1):36\u201342.","journal-title":"Hematol Oncol"},{"issue":"2","key":"3789_CR4","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41375-020-01072-6","volume":"35","author":"T Wen","year":"2021","unstructured":"Wen T, Wang J, Shi Y, Qian H, Liu P. Inhibitors targeting Bruton\u2019s tyrosine kinase in cancers: drug development advances. Leukemia. 2021;35(2):312\u201332.","journal-title":"Leukemia"},{"issue":"1","key":"3789_CR5","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1177\/10781552231216886","volume":"30","author":"DD Davis","year":"2024","unstructured":"Davis DD, Ohana Z, Pham HM. Pirtobrutinib: a novel non-covalent BTK inhibitor for the treatment of adults with relapsed\/refractory mantle cell lymphoma. J Oncol Pharm Pract. 2024;30(1):182\u20138.","journal-title":"J Oncol Pharm Pract"},{"issue":"9","key":"3789_CR6","doi-asserted-by":"publisher","first-page":"e682","DOI":"10.1016\/S2352-3026(24)00172-8","volume":"11","author":"WG Wierda","year":"2024","unstructured":"Wierda WG, Shah NN, Cheah CY, Lewis D, Hoffmann MS, Coombs CC, et al. Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1\/2 BRUIN study. Lancet Haematol. 2024;11(9):e682\u201392.","journal-title":"Lancet Haematol"},{"issue":"6","key":"3789_CR7","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/ajh.25796","volume":"95","author":"S Zhao","year":"2020","unstructured":"Zhao S, Kanagal-Shamanna R, Navsaria L, Ok CY, Zhang S, Nomie K, et al. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL)\u2014outcomes and mutation profile from venetoclax resistant MCL patients. Am J Hematol. 2020;95(6):623\u20139.","journal-title":"Am J Hematol"},{"issue":"14","key":"3789_CR8","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331\u201342.","journal-title":"N Engl J Med"},{"issue":"2","key":"3789_CR9","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","volume":"111","author":"E Hoster","year":"2008","unstructured":"Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111(2):558\u201365.","journal-title":"Blood"},{"issue":"4","key":"3789_CR10","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1182\/blood-2017-07-797019","volume":"131","author":"SM Aukema","year":"2018","unstructured":"Aukema SM, Hoster E, Rosenwald A, Canoni D, Delfau-Larue MH, Rymkiewicz G, et al. Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL network. Blood. 2018;131(4):417\u201320.","journal-title":"Blood"},{"issue":"45","key":"3789_CR11","doi-asserted-by":"publisher","first-page":"18250","DOI":"10.1073\/pnas.1314608110","volume":"110","author":"S Bea","year":"2013","unstructured":"Bea S, Valdes-Mas R, Navarro A, Salaverria I, Martin-Garcia D, Jares P, et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci U S A. 2013;110(45):18250\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"17","key":"3789_CR12","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","volume":"130","author":"CW Eskelund","year":"2017","unstructured":"Eskelund CW, Dahl C, Hansen JW, Westman M, Kolstad A, Pedersen LB, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017;130(17):1903\u201310.","journal-title":"Blood"},{"issue":"5\u20136","key":"3789_CR13","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41417-018-0022-5","volume":"25","author":"P Yang","year":"2018","unstructured":"Yang P, Zhang W, Wang J, Liu Y, An R, Jing H. Genomic landscape and prognostic analysis of mantle cell lymphoma. Cancer Gene Ther. 2018;25(5\u20136):129\u201340.","journal-title":"Cancer Gene Ther"},{"issue":"5","key":"3789_CR14","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1111\/bjh.13349","volume":"169","author":"Y Oki","year":"2015","unstructured":"Oki Y, Neelapu SS, Fanale M, Kwak LW, Fayad L, Rodriguez MA, et al. Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next-generation sequencing approach. Br J Haematol. 2015;169(5):689\u201393.","journal-title":"Br J Haematol"},{"issue":"5","key":"3789_CR15","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S1470-2045(15)70106-3","volume":"16","author":"M Roschewski","year":"2015","unstructured":"Roschewski M, Dunleavy K, Pittaluga S, Moorhead M, Pepin F, Kong K, et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol. 2015;16(5):541\u20139.","journal-title":"Lancet Oncol"},{"issue":"364","key":"3789_CR16","doi-asserted-by":"publisher","first-page":"364ra155","DOI":"10.1126\/scitranslmed.aai8545","volume":"8","author":"F Scherer","year":"2016","unstructured":"Scherer F, Kurtz DM, Newman AM, Stehr H, Craig AF, Esfahani MS, et al. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci Transl Med. 2016;8(364):364ra155.","journal-title":"Sci Transl Med"},{"issue":"14","key":"3789_CR17","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1182\/blood-2016-05-719641","volume":"129","author":"D Rossi","year":"2017","unstructured":"Rossi D, Diop F, Spaccarotella E, Monti S, Zanni M, Rasi S, et al. Diffuse large B-cell lymphoma genotyping on the liquid biopsy. Blood. 2017;129(14):1947\u201357.","journal-title":"Blood"},{"issue":"28","key":"3789_CR18","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","volume":"36","author":"DM Kurtz","year":"2018","unstructured":"Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, Esfahani MS, et al. Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma. J Clin Oncol. 2018;36(28):2845\u201353.","journal-title":"J Clin Oncol"},{"issue":"22","key":"3789_CR19","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","volume":"131","author":"V Spina","year":"2018","unstructured":"Spina V, Bruscaggin A, Cuccaro A, Martini M, Di Trani M, Forestieri G, et al. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. Blood. 2018;131(22):2413\u201325.","journal-title":"Blood"},{"issue":"1","key":"3789_CR20","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41375-019-0541-6","volume":"34","author":"AK Desch","year":"2020","unstructured":"Desch AK, Hartung K, Botzen A, Brobeil A, Rummel M, Kurch L, et al. Genotyping circulating tumor DNA of pediatric Hodgkin lymphoma. Leukemia. 2020;34(1):151\u201366.","journal-title":"Leukemia"},{"issue":"1","key":"3789_CR21","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3324\/haematol.2019.237719","volume":"106","author":"V Camus","year":"2021","unstructured":"Camus V, Viennot M, Lequesne J, Viailly PJ, Bohers E, Bessi L, et al. Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study. Haematologica. 2021;106(1):154\u201362.","journal-title":"Haematologica"},{"issue":"27","key":"3789_CR22","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059\u201368.","journal-title":"J Clin Oncol"},{"issue":"15","key":"3789_CR23","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","volume":"30","author":"AM Bolger","year":"2014","unstructured":"Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30(15):2114\u201320.","journal-title":"Bioinformatics"},{"issue":"3","key":"3789_CR24","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1101\/gr.129684.111","volume":"22","author":"DC Koboldt","year":"2012","unstructured":"Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012;22(3):568\u201376.","journal-title":"Genome Res"},{"issue":"1","key":"3789_CR25","doi-asserted-by":"publisher","first-page":"6450","DOI":"10.1038\/s41467-021-26806-7","volume":"12","author":"SY Liu","year":"2021","unstructured":"Liu SY, Bao H, Wang Q, Mao WM, Chen Y, Tong X, et al. Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes. Nat Commun. 2021;12(1):6450.","journal-title":"Nat Commun"},{"issue":"16","key":"3789_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkw520","volume":"44","author":"R Shen","year":"2016","unstructured":"Shen R, Seshan VE. FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res. 2016;44(16): e131.","journal-title":"Nucleic Acids Res"},{"key":"3789_CR27","unstructured":"Shah Ronak. icallSV: A Framework to call Structural Variants from NGS based datasets. 2017; Available from: https:\/\/github.com\/rhshah\/iCallSV."},{"key":"3789_CR28","unstructured":"Shah Ronak. iAnnotateSV: Annotation of structural variants detected from NGS. 2021; Available from: https:\/\/github.com\/rhshah\/iAnnotateSV."},{"issue":"5","key":"3789_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002223","volume":"9","author":"X Huang","year":"2021","unstructured":"Huang X, He M, Peng H, Tong C, Liu Z, Zhang X, et al. Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CLAP trial. J Immunother Cancer. 2021;9(5): e002223.","journal-title":"J Immunother Cancer"},{"key":"3789_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216569","volume":"582","author":"Y Yang","year":"2024","unstructured":"Yang Y, Wang J, Wang J, Zhao X, Zhang T, Yang Y, et al. Unrevealing the therapeutic benefits of radiotherapy and consolidation immunotherapy using ctDNA-defined tumor clonality in unresectable locally advanced non-small cell lung cancer. Cancer Lett. 2024;582: 216569.","journal-title":"Cancer Lett"},{"issue":"2","key":"3789_CR31","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","volume":"173","author":"F Sanchez-Vega","year":"2018","unstructured":"Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, et al. Oncogenic signaling pathways in the cancer genome atlas. Cell. 2018;173(2):321\u201337.","journal-title":"Cell"},{"key":"3789_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.17.00011","volume":"2017","author":"D Chakravarty","year":"2017","unstructured":"Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J, et al. OncoKB: a precision oncology knowledge base. JCO Precis Oncol. 2017;2017:1\u201316.","journal-title":"JCO Precis Oncol"},{"issue":"3","key":"3789_CR33","doi-asserted-by":"publisher","first-page":"690","DOI":"10.3324\/haematol.2020.274258","volume":"107","author":"MCJ Ma","year":"2022","unstructured":"Ma MCJ, Tadros S, Bouska A, Heavican T, Yang H, Deng Q, et al. Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma. Haematologica. 2022;107(3):690\u2013701.","journal-title":"Haematologica"},{"key":"3789_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14796694.2024.2402209","volume":"20","author":"X Zhang","year":"2024","unstructured":"Zhang X, Yang L, Zhu M, Zhao X, Xiao Y, Pang J, et al. The clinical utility of plasma circulating tumor DNA in the diagnosis and disease surveillance in non-diffuse large B-cell non-Hodgkin lymphomas. Future Oncol. 2024;20:1\u201311.","journal-title":"Future Oncol"},{"issue":"5","key":"3789_CR35","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S1470-2045(18)30145-1","volume":"19","author":"A Italiano","year":"2018","unstructured":"Italiano A, Soria JC, Toulmonde M, Michot JM, Lucchesi C, Varga A, et al. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncol. 2018;19(5):649\u201359.","journal-title":"Lancet Oncol"},{"issue":"1","key":"3789_CR36","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1186\/s12916-022-02562-3","volume":"20","author":"M Li","year":"2022","unstructured":"Li M, Mi L, Wang C, Wang X, Zhu J, Qi F, et al. Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy. BMC Med. 2022;20(1):369.","journal-title":"BMC Med"},{"key":"3789_CR37","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau1167","author":"L Zhang","year":"2019","unstructured":"Zhang L, Yao Y, Zhang S, Liu Y, Guo H, Ahmed M, et al. Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma. Sci Transl Med. 2019. https:\/\/doi.org\/10.1126\/scitranslmed.aau1167.","journal-title":"Sci Transl Med"},{"issue":"12","key":"3789_CR38","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1158\/1535-7163.MCT-21-0433","volume":"20","author":"K Mardinian","year":"2021","unstructured":"Mardinian K, Adashek JJ, Botta GP, Kato S, Kurzrock R. SMARCA4: implications of an altered chromatin-remodeling gene for cancer development and therapy. Mol Cancer Ther. 2021;20(12):2341\u201351.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"3789_CR39","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41591-018-0243-z","volume":"25","author":"R Agarwal","year":"2019","unstructured":"Agarwal R, Chan YC, Tam CS, Hunter T, Vassiliadis D, Teh CE, et al. Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma. Nat Med. 2019;25(1):119\u201329.","journal-title":"Nat Med"},{"key":"3789_CR40","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.gde.2013.11.005","volume":"24","author":"B Heidenreich","year":"2014","unstructured":"Heidenreich B, Rachakonda PS, Hemminki K, Kumar R. TERT promoter mutations in cancer development. Curr Opin Genet Dev. 2014;24:30\u20137.","journal-title":"Curr Opin Genet Dev"},{"issue":"2","key":"3789_CR41","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ctrv.2003.07.007","volume":"30","author":"JA Fresno Vara","year":"2004","unstructured":"Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M. PI3K\/Akt signalling pathway and cancer. Cancer Treat Rev. 2004;30(2):193\u2013204.","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"3789_CR42","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/cmi.2012.61","volume":"10","author":"Z Hua","year":"2013","unstructured":"Hua Z, Hou B. TLR signaling in B-cell development and activation. Cell Mol Immunol. 2013;10(2):103\u20136.","journal-title":"Cell Mol Immunol"},{"issue":"6","key":"3789_CR43","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507\u201316.","journal-title":"N Engl J Med"},{"issue":"16","key":"3789_CR44","doi-asserted-by":"publisher","first-page":"3586","DOI":"10.1158\/1078-0432.CCR-14-2225","volume":"21","author":"RA de Claro","year":"2015","unstructured":"de Claro RA, McGinn KM, Verdun N, Lee SL, Chiu HJ, Saber H, et al. FDA approval: ibrutinib for patients with previously treated mantle cell lymphoma and previously treated chronic lymphocytic leukemia. Clin Cancer Res. 2015;21(16):3586\u201390.","journal-title":"Clin Cancer Res"},{"issue":"24","key":"3789_CR45","doi-asserted-by":"publisher","first-page":"3988","DOI":"10.1200\/JCO.23.00562","volume":"41","author":"ML Wang","year":"2023","unstructured":"Wang ML, Jurczak W, Zinzani PL, Eyre TA, Cheah CY, Ujjani CS, et al. Pirtobrutinib in covalent bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma. J Clin Oncol. 2023;41(24):3988\u201397.","journal-title":"J Clin Oncol"},{"issue":"7","key":"3789_CR46","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.3390\/ijms22073464","volume":"22","author":"R Mishra","year":"2021","unstructured":"Mishra R, Patel H, Alanazi S, Kilroy MK, Garrett JT. PI3K inhibitors in cancer: clinical implications and adverse effects. Int J Mol Sci. 2021;22(7):3464.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"3789_CR47","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1158\/1535-7163.MCT-15-0945","volume":"15","author":"M Choi","year":"2016","unstructured":"Choi M, Kipps T, Kurzrock R. ATM mutations in cancer: therapeutic implications. Mol Cancer Ther. 2016;15(8):1781\u201391.","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"3789_CR48","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1158\/1535-7163.MCT-19-0208","volume":"18","author":"SA Armstrong","year":"2019","unstructured":"Armstrong SA, Schultz CW, Azimi-Sadjadi A, Brody JR, Pishvaian MJ. ATM dysfunction in pancreatic adenocarcinoma and associated therapeutic implications. Mol Cancer Ther. 2019;18(11):1899\u2013908.","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"3789_CR49","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1371\/journal.pgen.0030190","volume":"3","author":"X Estivill","year":"2007","unstructured":"Estivill X, Armengol L. Copy number variants and common disorders: filling the gaps and exploring complexity in genome-wide association studies. PLoS Genet. 2007;3(10):1787\u201399.","journal-title":"PLoS Genet"},{"issue":"6","key":"3789_CR50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0100371","volume":"9","author":"SS Mokhtar","year":"2014","unstructured":"Mokhtar SS, Marshall CR, Phipps ME, Thiruvahindrapuram B, Lionel AC, Scherer SW, Peng HB. Novel population specific autosomal copy number variation and its functional analysis amongst Negritos from Peninsular Malaysia. PLoS ONE. 2014;9(6): e100371.","journal-title":"PLoS ONE"},{"issue":"20","key":"3789_CR51","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1093\/bioinformatics\/btn421","volume":"24","author":"I Ionita-Laza","year":"2008","unstructured":"Ionita-Laza I, Laird NM, Raby BA, Weiss ST, Lange C. On the frequency of copy number variants. Bioinformatics. 2008;24(20):2350\u20135.","journal-title":"Bioinformatics"},{"issue":"4","key":"3789_CR52","doi-asserted-by":"publisher","first-page":"djv362","DOI":"10.1093\/jnci\/djv362","volume":"108","author":"C Le Tourneau","year":"2016","unstructured":"Le Tourneau C, Kamal M, Tsimberidou AM, Bedard P, Pierron G, Callens C, et al. Treatment algorithms based on tumor molecular profiling: the essence of precision medicine trials. J Natl Cancer Inst. 2016;108(4):djv362.","journal-title":"J Natl Cancer Inst"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-025-03789-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-025-03789-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-025-03789-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T13:02:55Z","timestamp":1746277375000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-025-03789-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,3]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3789"],"URL":"https:\/\/doi.org\/10.1186\/s12935-025-03789-9","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,3]]},"assertion":[{"value":"28 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of Hunan Cancer Hospital (No. 2024\u2013152). Written informed consent was obtained from each patient before sample collection.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"S. Wang, X.Y. Wu, Q.X. Ou, H. Bao, and W. Yang are employees of Nanjing Geneseeq Technology Inc. The remaining authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"172"}}